Adalimumab-associated intracranial Neisseria meningitidis infection
10.3760/cma.j.cn114015-20241015-00092
- VernacularTitle:阿达木单抗致颅内脑膜炎奈瑟菌感染
- Author:
Jiejie GUANG
1
;
Zhonghua ZHU
1
Author Information
1. 安徽省黄山市人民医院药剂科，黄山 245000
- Publication Type:Journal Article
- Keywords:
Adalimumab;
Neisseria meningitidis;
Central nervous system bacterial infection;
Spondylitis, ankylosing;
Tumor necrosis factor inhibitors
- From:
Adverse Drug Reactions Journal
2025;27(8):505-507
- CountryChina
- Language:Chinese
-
Abstract:
A 39-year-old male patient with ankylosing spondylitis received adalimumab 40 mg subcutaneously every 2 weeks plus sulfasalazine enteric-coated tablets 0.75 g orally twice daily. Two weeks after the therapy initiation, he received his second adalimumab injection and discontinued sulfasalazine because of skin rashes. Meanwhile, cetirizine 10 mg once daily was given as anti-allergic treatment for 3 days. Six days later, he developed fever and persistent holocranial dull pain. The next day the headache worsened, with one episode of vomiting gastric contents. Cranial magnetic resonance imaging revealed findings consistent with infectious leptomeningeal lesions, and cerebrospinal fluid analysis suggested intracranial infection. Empirical anti-infection therapy with ceftriaxone and ganciclovir, as well as intracranial pressure reduction therapy with 20% mannitol was initiated. Two days later, next-generation sequencing of cerebrospinal fluid identified Neisseria meningitidis as the highly probable pathogen. The therapy regimen was adjusted to ceftriaxone, acyclovir and dexamethasone. After 12 days of treatments, the patient achieved full clinical recovery from meningitis.
